Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | January 27, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tempest Therapeutics, Inc.
Report date January 27, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26 | Direct | 1,230 |
Reported balance
After 2026-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2026 Filed Jan 28, 2026 16:30 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 1,230 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001214505-26-000003 · form4-01282026_040101.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,230 Underlying: Common Stock · 1,230 shares Expires 2036-01-26 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 18:05 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001415889-24-017011 · form4-06142024_060605.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 16:50 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-23-038448 · doc4.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock · 8,200 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 16:16 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001179110-22-003380 · edgar.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 17:56 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 6,635 | Not disclosed Strike: $11.07 | Not disclosed |
DisclosureSEC source: 0001140361-21-023540 · form4.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Underlying: Common Stock · 6,635 shares Expires 2031-06-30 F1 · price: One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| July 01, 2021 Filed Sep 20, 2021 20:34 UTC Amendment | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 6,635 | $0.00 Strike: $11.07 | $0.00 |
DisclosureSEC source: 0001179110-21-008869 · edgar.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Underlying: Common Stock · 6,635 shares Expires 2031-06-30 F1 · derivative.exercise_date: Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 07:05 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001544227-20-000030 · wf-form4_159291032774054.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 17:23 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $6.29 | $0.00 |
DisclosureSEC source: 0001209191-19-061358 · doc4.xml · derivative · entry 1 NICHOL GEOFFREY · CIK 0001214505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-12-16 F1 · derivative.exercise_date: One third (1/3rd) of the shares subject to the option shall vest on December 17, 2020, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.